Nine Masts Capital’s Altimmune ALT Stock Holding History

Nine Masts Capital’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,850	Closed	-$36.5K	–	173
2026 Q1	$36.5K	Buy	+11,850	New	+$50.3K	0.01%	195

Other funds holding ALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nine Masts Capital's ALT Position: Q2 2026 in Review

Nine Masts Capital sold out of Altimmune (ALT) in Q2 2026, closing a stake of 11,850 shares — an estimated $36.5K sold.

Nine Masts Capital first reported a position in ALT in Q1 2026 and held it in 1 quarter. The position peaked at $36.5K in Q1 2026. 210 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

Nine Masts Capital reported no remaining Altimmune position as of Q2 2026 after selling out during the quarter.
Nine Masts Capital sold 11,850 Altimmune shares in Q2 2026, an estimated $36.5K.
Nine Masts Capital first reported a position in Altimmune in Q1 2026 and held it in 1 quarter.
Nine Masts Capital's Altimmune position peaked at $36.5K in Q1 2026.
210 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.